How to Treat AML SH
Vienna , Austria
Due to the rarity of the disease, data are lacking on the relationships between AML and most risk factors, and strong connections have not been made through epidemiological studies.
Secondary Acute Myeloid Leukaemia occurs more frequently in the elderly AML population than in younger patients and is typically more difficult to treat as it is less responsive to standard chemotherapies.
The cause of AML is unknown; however, several risk factors have been associated with increased chance of developing AML, including, age, male sex, a history of smoking, and exposure to high doses of radiation and cytotoxic chemicals.
Pleco’s team is working strenuously on the development of the PlecoidTM agents to increase the survival rate of patients with AML which is a disease carrying a poor prognosis.
World Lung Cancer Day is taking place on the 1st of August 2021, PlecoTherapeutics is taking the opportunity to raise awareness to support patients and their families, especially those affected by Small Cell Lung Cancer (SCLC).
Ivo Timmermans, Pleco’s CEO will be speaking at the Digital Conference Findacure’s annual Drug Repurposing Conference for RareDiseases on the 16th of June 2021.
Pleco Therapeutics’ CEO, Ivo Timmermans will present at the Investment Webinar organized by Ruffena Capital on the Tuesday 8th of June 2021 at 2pm.
Pleco Therapeutics aims to extend and enhance the lives of patients through its novel Plecoid therapies that increase the effectiveness of current cancer treatments.
Pleco is a proud finalist of Global Investor Forum 2021! Do you want to see us in the finale on 15 April during Innovation for Health?
We are pleased to inform you that our board members Ivo Timmermans, Rudi Jansen and Gerben de Rijk will attend the 7th Annual LSX World Congress. This meeting will be delivered virtually, from 1 to 12 February
We are excited to share that our board members Ivo Timmermans and Rudi Jansen will attend the LSX World Congress in London. Our CEO Ivo Timmermans will give a presentation at the Biotech Showcase event
Our Chief Business Officer Rudi Jansen will be attending the Convention on Pharmaceutical Ingredients (CPHI Worldwide) in Frankfurt, Germany.